Author: Ken Dropiewski

New data further strengthens important role of LIXIANA® (edoxaban) in managing complex patient populations with atrial fibrillation (AF)

Data from the ETNA-AF-Europe Registry provide insights on edoxaban in routine clinical practice in patient subpopulations including those who are frail, with heart failure or insulin-dependent diabetes1,2,3 Latest findings presented at the European Society of Cardiology (ESC) Congress 2022 add to the wealth of edoxaban data reinforcing its safety and […]

Bayer Initiates Phase III Study Program for Investigational Oral FXIa Inhibitor Asundexian

The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in the prevention of stroke events in patients with atrial fibrillation as well as patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack1,2 OCEANIC-AF and OCEANIC-STROKE are expected to enroll up […]

Late-Breaking Results From Phase 2 AXIOMATIC-SSP Study of Milvexian, an Investigational Oral Factor XIa Inhibitor, Show Favorable Antithrombotic Profile in Combination With Dual Antiplatelet Therapy

~30% relative risk reduction seen in symptomatic ischemic strokes in three milvexian arms compared to placebo; dose response not observed for primary study objective No fatal bleeding and no increase in symptomatic intracranial hemorrhage observed in patients treated with milvexian, even with all patients receiving 21 days of background dual […]

BD Promotes Two Senior Executives to Segment Leadership Roles

Mike Garrison Named EVP and President, Medical segment Rick Byrd Named EVP and President, Interventional segment FRANKLIN LAKES, N.J., Aug. 25, 2022 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of two senior leaders to segment president roles. Michael (Mike) Garrison has been named executive […]

Large Atrial Thrombus Percutaneously Removed Using the ŌNŌ Retrieval System ŌNŌCOR Reports First-In-Human Use for Removal of an Atrial Blood Clot

PHILADELPHIA, Aug. 25, 2022 (GLOBE NEWSWIRE) — ŌNŌCOR LLC announced the use of the ŌNŌ endovascular retrieval system to remove a large central-line-associated thrombus from the right atrium in a teenage patient. The team at Children’s Hospital Los Angeles (CHLA, @ChildrensLA), led by Dr. Darren Berman, Director of Congenital Interventional Catheterization with CHLA’s Heart Institute, […]

Philips spotlights integrated, data-driven cardiology solutions at ESC 2022

Philips AI-powered interventional and diagnostic smart systems and at-home solutions connect care across the cardiology care pathway to enhance diagnostic confidence, drive greater efficiency, and improve patient outcomes Amsterdam, the Netherlands and Barcelona, Spain – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, will showcase its latest integrated […]

New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced STEMI as Well as Other MI Subtypes

— Late-Breaking Data Show VASCEPA/VAZKEPA Significantly Reduced STEMI by 40% and NSTEMI by 27% in Pre-Specified, Post Hoc Analyses — — Data Presented During Late-Breaking Science Session at European Society of Cardiology (ESC) Congress 2022 in Barcelona — DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 26, 2022 (GLOBE NEWSWIRE) — Amarin […]

Imbria Presents Positive Clinical Data for Ninerafaxstat from IMPROVE-DiCE at the European Society of Cardiology Congress 2022

Treatment with ninerafaxstat significantly improved cardiac energetics, steatosis and left ventricular (LV) diastolic function in patients with type-2 diabetes mellitus (T2DM) and obesity BOSTON, Mass., Aug. 26, 2022 (GLOBE NEWSWIRE) — Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced positive […]

Esperion Announces Bempedoic Acid (NEXLETOL®) Recommended as Oral Non-Statin Therapy for LDL-Cholesterol Lowering in American College of Cardiology Expert Consensus Decision Pathway

ANN ARBOR, Mich., Aug. 26, 2022 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that bempedoic acid (NEXLETOL®) is now recommended as an important oral non-statin therapy for LDL-cholesterol (LDL-C) lowering in the management of atherosclerotic cardiovascular disease (ASCVD) by the American College of Cardiology (ACC) task force on expert […]